Group 1: Company Overview - The company is 中山大学达安基因股份有限公司, with the stock code 002030 and the abbreviation 达安基因 [1] - The investor relations activity was conducted on December 3, 2014, at the company headquarters in Guangzhou [1] Group 2: Collaboration and Product Applications - The collaboration with LIFE company is non-exclusive, allowing other companies to use its instruments [2] - The second-generation gene sequencer and related reagents are currently applied in non-invasive prenatal screening clinical applications, with ongoing research for other application areas [2] Group 3: Customer Base and Market Insights - The primary customers for the second-generation gene sequencing products are major hospitals in China [2] - Independent laboratories are emerging, with differences in operational models between domestic and international markets [3] Group 4: Future Development and Strategy - The company will decide on establishing new independent laboratories based on market conditions, with a focus on enhancing profitability [3] - The strategic goal is to become a leading integrated supplier in the diagnostic industry, with opportunities across all segments of the supply chain [3] - There are currently no plans for mergers or acquisitions, as the market space remains challenging to explore [4]

Group 1: Business Overview - The main revenue sources of the company include reagent income, instrument income, and service income, with PCR diagnostic reagents being the primary contributor to reagent income [2][3] - In 2014, the service revenue's operating cost increased by 88.04% compared to the previous year due to aggressive marketing efforts for independent laboratory services [3] - The company plans to enhance the profitability of independent laboratories rather than simply expanding the number of labs [3][4] Group 2: Financial Performance - In 2014, the revenue from PCR diagnostic reagents exceeded 500 million, accounting for approximately 80% of the reagent income, with an annual growth rate of around 20% [4] - The company's operating revenue grew by 27.13% in 2014, but net profit growth was significantly lower due to a substantial decrease in investment income compared to the previous year [4] Group 3: Future Growth and Strategy - The company is focusing on industry chain layout and is investing in specialized companies through equity participation [5] - The second-generation gene sequencing business is being developed through two subsidiaries, with one focusing on prenatal testing and the other providing testing services [4]

Group 1: Company Partnerships - The company has established a joint venture with Life Technologies, focusing on the development of sequencing reagents, with Life Technologies providing sequencing equipment [1][2] - The collaboration with Guangzhou Zhongda Holdings aims to integrate medical resources from Sun Yat-sen University, enhancing social benefits and optimizing existing assets [2][3] Group 2: Financial Status - The company currently has no financing needs, with normal operational conditions and no issues regarding bank credit or equity pledges [3] - The company is not facing any funding shortages [3] Group 3: Support and Governance - Sun Yat-sen University is the actual controller of the company but does not interfere in daily management, which operates under a well-structured market-oriented governance model [3] - The company is positioned above average among listed companies affiliated with universities in terms of marketization [3] Group 4: Future Development - The company focuses on molecular diagnostic technology and does not rule out future expansion into therapeutic areas, while currently prioritizing the integration of the diagnostic industry chain [4] - The stock option incentive plan was confirmed and filed with the regulatory authority, with plans to submit it for board and shareholder approval [4]

附件: RENTW :42 . 用文报 n a man (B 具新技术企业 8 发表网 204 注：从左起瑞银证券有限责任公司执行董事季序我、公司董事会秘书张斌、公司证券事务代 表曾宇婷合影留念。 ...

Group 1: Company Representation - The company board secretary, Zhang Bin, is present in the front row [2] - The company securities representative, Zeng Yuting, is also present in the back row [4] - Various institutional researchers from firms such as Guotai Junan, Chuang Hai Fu Xin, and others are photographed together [5] Group 2: Institutional Collaboration - The collaboration includes institutions like Dongguan Securities, Nuoan Fund, and CITIC Securities [5] - Other participating institutions are Zhongshan Securities, Congrong Investment, Guangdong Yinshi Investment, and Guangdong Huizheng Investment [5] - The presence of Lianxun Securities among the institutional researchers indicates a broad engagement [5]

Group 1: Company Representatives - The company’s securities affairs representative, Zeng Yuting, and board secretary, Zhang Bin, were present with researchers from various investment firms [2][3] Group 2: Institutional Collaborations - Collaborating institutions include Franklin Templeton Securities Investment Trust Co., Ltd., Guosen Securities Co., Ltd., Hanlun Investment Consulting (Shanghai) Co., Ltd., and Future Asset Yicai Investment Consulting (Shanghai) Co., Ltd. [2][3]

Group 1: Interaction Highlights - The chairman of Da An Gene, He Yunshao, and the board secretary, Zhang Bin, engaged with investors during the event [1] Group 2: Visual Documentation - Photos capturing the interaction between the chairman and investors were included in the report [1]